What Slowdown? Sales Rep Demand Robust In China
This article was originally published in Scrip
A college degree used to be the door-opener for many Chinese graduates to start selling drugs for multinational pharma companies. Demand remains strong, but the bar is rising, and some notable changes will shape the industry for years to come, industry observers say.
You may also be interested in...
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.
Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research.
China is nearing the finish line in the coronavirus vaccines race with just “the last kilometer to go”, and its government is already negotiating with the WHO for potential global supplies.